πŸ”₯πŸ” BizChicken πŸ”πŸ”₯

Companies Similar to Assertio Holdings, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Assertio Holdings, Inc.

Assertio Holdings, Inc. logo
Market Cap: Low
Employees: Lowest

INDOCIN, CAMBIA, Zipsor, SPRIX, Otrexup

Assertio Holdings, Inc. is a specialty pharmaceutical company delivering medicines for neurology, hospital, pain, and inflammation, including treatments for arthritis, migraines, and more.

Tags: arthritis, migraine, neurology, pain management, pharmaceutical

Symbol: ASRT

Recent Price: $0.88

Industry: Drug Manufacturers - Specialty & Generic

CEO: Mr. Brendan P. O'Grady

Sector: Healthcare

Employees: 53

Address: 100 South Saunders Road, Lake Forest, IL 60045

Phone: 224 419 7106

Leadership

  • Brendan P O’Grady, Chief Executive Officer of Assertio Holdings
  • Sravan Emany, Chief Financial Officer, Ironwood Pharmaceuticals
  • Heather Mason, Former Senior Executive of Abbott Laboratories
  • Jeffrey Vacirca, CEO and Chairman of the Board of New York Cancer & Blood Specialists
  • Peter D. Staple, Chairman of the Board of Directors
  • Sigurd C. Kirk, Former Executive Vice President, Allergan plc.
  • William T. McKee, Former Chief Financial Officer, Barr Pharmaceuticals

Last updated: 2024-12-31

Biogen Inc.

Biogen Inc. logo
Market Cap: Highest
Employees: Highest

TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, FAMPYRA, SPINRAZA, FUMADERM, BENEPALI, ADUHELM, IMRALDI, FLIXABI, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS

Biogen Inc. focuses on discovering, developing, manufacturing, and delivering therapies for neurological and neurodegenerative diseases, including multiple sclerosis, spinal muscular atrophy, plaque psoriasis, Alzheimer's disease, and various cancers and autoimmune conditions.

Tags: biotechnology, multiple sclerosis, neurodegenerative diseases, neurological diseases, pharmaceuticals

Symbol: BIIB

Recent Price: $150.19

Industry: Drug Manufacturers - General

CEO: Mr. Christopher A. Viehbacher

Sector: Healthcare

Employees: 7570

Address: 225 Binney Street, Cambridge, MA 02142

Phone: 617 679 2000

Leadership

  • Christopher A. Viehbacher, President and Chief Executive Officer
  • Susan H. Alexander, Chief Legal Officer
  • Ginger Gregory, Ph.D., Chief Human Resources Officer
  • Jane Grogan, Ph.D., Head of Research
  • Rachid Izzar, Head of Global Product Strategy & Commercialization
  • Adam Keeney, Head of Corporate Development
  • Michael McDonnell, Chief Financial Officer
  • Nicole Murphy, Head of Pharmaceutical Operations and Technology
  • Priya Singhal, M.D., M.P.H., Head of Development and Interim Chief Medical Officer
  • Alisha Alaimo, President, Head of North America
  • Stephen Amato, Head of Investor Relations
  • Natacha Gassenbach, Head of Corporate Affairs, Chief Communications Officer
  • Fraser Hall, President, Head of Intercontinental Region
  • Wolfram Schmidt, President, Head of Europe
  • Kendra Thomas, Head of Global Workforce Diversity, Equity & Inclusion (DE&I)
  • Caroline Dorsa, Chair of the Board
  • Maria C. Freire, Ph.D., Director
  • William A. Hawkins, Director
  • Susan Langer, Director
  • Jesus B. Mantas, Director
  • Lloyd B. Minor, M.D., Director
  • Monish Patolawala, Director
  • Eric K. Rowinsky, M.D., Director
  • Stephen A. Sherwin, M.D., Director

Last updated: 2024-12-31

ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals, Inc. logo
Market Cap: Medium
Employees: Low

ORIC-533, ORIC-944, ORIC-114

ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that discovers and develops therapies for the treatment of cancers, focusing on overcoming resistance in chemotherapy and immunotherapy. Their product candidates target various cancer resistance mechanisms, including prostate cancer and epidermal growth factor receptor mutations.

Tags: ORIC-114, ORIC-533, ORIC-944, biopharmaceutical, cancer treatment, clinical-stage

Symbol: ORIC

Recent Price: $8.17

Industry: Biotechnology

CEO: Dr. Jacob M. Chacko M.B.A., M.D.

Sector: Healthcare

Employees: 107

Address: 240 East Grand Avenue, South San Francisco, CA 94080

Phone: 650 388 5600

Last updated: 2024-12-31

Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc. logo
Market Cap: Low
Employees: Low

Therapeutic Candidates (INBRX-109, INBRX-106)

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops biologic therapeutics for life-threatening conditions, with therapeutic candidates in phase 2 clinical trials targeting various cancers.

Tags: biologic therapeutics, biopharmaceutical, cancer treatment, clinical-stage

Symbol: INBX

Recent Price: $15.14

Industry: Biotechnology

CEO: Mr. Mark Paul Lappe

Sector: Healthcare

Employees: 166

Address: 11025 North Torrey Pines Road, La Jolla, CA 92037

Phone: 858-795-4220

Last updated: 2024-12-31

Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc. logo
Market Cap: High
Employees: Low

SNDX-5613, SNDX-6352 (axatilimab), Entinostat

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer treatment, including innovative candidates like SNDX-5613 and SNDX-6352. It collaborates with notable institutions like the National Cancer Institute and has a license agreement with Kyowa Hakko Kirin Co., Ltd.

Tags: Collaborations, Entinostat, Monoclonal Antibody, SNDX-5613, SNDX-6352, biopharmaceutical, cancer therapy, clinical-stage

Symbol: SNDX

Recent Price: $12.52

Industry: Biotechnology

CEO: Mr. Michael A. Metzger M.B.A.

Sector: Healthcare

Employees: 184

Address: 35 Gatehouse Drive, Waltham, MA 02451

Phone: 781 419 1400

Last updated: 2024-12-31

Aquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

Sympazan, Suboxone, Zuplenz, Azstarys, Libervant, Exservan

Aquestive Therapeutics, Inc. is a pharmaceutical company committed to identifying, developing, and commercializing innovative products to address unmet medical needs, both in the U.S. and globally. It specializes in oral soluble film formulations for various treatments, including neurological conditions and opioid dependence.

Tags: ADHD, ALS, biotechnology, neurology, opioid dependence, oral soluble film, pharmaceutical

Symbol: AQST

Recent Price: $3.52

Industry: Drug Manufacturers - Specialty & Generic

CEO: Mr. Daniel Barber

Sector: Healthcare

Employees: 135

Address: 30 Technology Drive, Warren, NJ 07059

Phone: 908 941 1900

Last updated: 2024-12-31

Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc. logo
Market Cap: High
Employees: Medium

AXS-05, AXS-07, AXS-12, AXS-14

Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapies for central nervous system disorders such as major depressive disorder, migraine, narcolepsy, and fibromyalgia.

Tags: CNS disorders, biopharmaceutical, clinical trials, depression, fibromyalgia, migraine, narcolepsy

Symbol: AXSM

Recent Price: $84.78

Industry: Biotechnology

CEO: Dr. Herriot Tabuteau M.D.

Sector: Healthcare

Employees: 589

Address: 22 Cortlandt Street, New York, NY 10007

Phone: 212 332 3241

Leadership

  • Herriot Tabuteau, MD, CHIEF EXECUTIVE OFFICER
  • Nick Pizzie, CPA, MBA, CHIEF FINANCIAL OFFICER
  • Mark Jacobson, MA, CHIEF OPERATING OFFICER
  • Hunter Murdock, Esq., GENERAL COUNSEL
  • ari Maizel, Executive Vice President, Head of Commercial
  • Mark Coleman, MD, DIRECTOR
  • Roger Jeffs, PhD, DIRECTOR
  • Susan Mahony, PhD, MBA, DIRECTOR
  • Mark Saad, DIRECTOR

Last updated: 2024-12-31

Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Inc. logo
Market Cap: Lowest
Employees: Low

Acetadote, Caldolor, Kristalose, Omeclamox-Pak, Vaprisol, Vibativ, Redi Trex

Cumberland Pharmaceuticals Inc. focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology, offering various medications including injections and oral solutions.

Tags: gastroenterology, hospital care, oncology, pharmaceutical, prescription products, rheumatology

Symbol: CPIX

Recent Price: $2.42

Industry: Drug Manufacturers - Specialty & Generic

CEO: Mr. A. J. Kazimi MBA

Sector: Healthcare

Employees: 91

Address: 2525 West End Avenue, Nashville, TN 37203

Phone: 615 255 0068

Last updated: 2024-12-31

Eton Pharmaceuticals, Inc.

Eton Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Lowest

Biorphen, Carglumic Acid, Rezipres, Alkindi Sprinkle, EPRONTIA, Alaway Preservative Free

Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for rare diseases, with a portfolio including treatments like Biorphen, Carglumic Acid, and others for various indications.

Tags: Alaway Preservative Free, Alkindi Sprinkle, Biorphen, Carglumic Acid, EPRONTIA, Pharmaceuticals, Rare Diseases, Rezipres

Symbol: ETON

Recent Price: $13.03

Industry: Biotechnology

CEO: Mr. Sean E. Brynjelsen

Sector: Healthcare

Employees: 30

Address: 21925 West Field Parkway, Deer Park, IL 60010-7208

Phone: 847 787 7361

Last updated: 2024-12-31

Incyte Corporation

Incyte Corporation logo
Market Cap: Highest
Employees: High

JAKAFI, PEMAZYRE, ICLUSIG

Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics, with products like JAKAFI, PEMAZYRE, and ICLUSIG for various cancer treatments.

Tags: ICLUSIG, JAKAFI, PEMAZYRE, biopharmaceutical, cancer treatment, clinical trials, oncology, therapeutics

Symbol: INCY

Recent Price: $68.42

Industry: Biotechnology

CEO: Mr. Herve Hoppenot

Sector: Healthcare

Employees: 2524

Address: 1801 Augustine Cut-Off, Wilmington, DE 19803

Phone: 302 498 6700

Leadership

  • HervΓ© Hoppenot, Chairman and Chief Executive Officer
  • Paula J. Swain, Executive Vice President, Human Resources
  • Pablo J. Cagnoni, M.D., President, Head of Research and Development
  • Steven H. Stein, M.D., Executive Vice President and Chief Medical Officer
  • Sheila A. Denton, J.D., Executive Vice President and General Counsel
  • Christiana Stamoulis, MBA, Executive Vice President and Chief Financial Officer
  • Barry P. Flannelly, PharmD, MBA, Executive Vice President and General Manager, North America
  • Denise Brashear, Vice President, Head of Global Communications
  • Vijay Iyengar, M.D., Executive Vice President, Global Medical Affairs, Product, and Partnership Strategy (GMAP2S)
  • Lee Heeson, Executive Vice President, Head of Incyte International
  • Michael Morrissey, Executive Vice President and Head of Global Technical Operations
  • Matteo Trotta, MBA, Executive Vice President, General Manager, U.S. Dermatology
  • Xiaozhao Wang, Ph.D., Associate Vice President, Head of Medicinal Chemistry
  • Julian C. Baker, Managing Partner
  • Jean-Jacques Bienaime, Former Chief Executive Officer
  • Otis Brawley, M.D., Bloomberg Distinguished Professor of Oncology and Epidemiology
  • Paul J. Clancy, Former Executive Vice President and Senior Advisor
  • Jacqualyn A. Fouse, Ph.D., Former Chief Executive Officer
  • Edmund P. Harrigan, M.D., Former Senior Vice President of Worldwide Safety and Regulatory
  • Katherine High, M.D., Former President and Head of Research and Development
  • Susanne Schaffert, Ph.D., Former President

Last updated: 2024-12-31

Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Low

DNA Medicines

Inovio Pharmaceuticals is a biotechnology company focused on discovering, developing, and commercializing DNA medicines to treat and protect against diseases like HPV, cancer, and infectious diseases. Their platform includes Syn Con designed DNA sequences and CELLECTRA smart devices technology for delivery.

Tags: DNA medicines, HPV, biotechnology, cancer, clinical studies, infectious diseases

Symbol: INO

Recent Price: $1.78

Industry: Biotechnology

CEO: Dr. Jacqueline E. Shea Ph.D.

Sector: Healthcare

Employees: 127

Address: 660 West Germantown Pike, Plymouth Meeting, PA 19462

Phone: 267 440 4200

Leadership

  • Jacqueline Shea, Ph.D., President & Chief Executive Officer
  • Peter Kies, Chief Financial Officer
  • Michael Sumner, MB BS, MBA, Chief Medical Officer
  • Laurent Humeau, Ph.D., Chief Scientific Officer; Chairman, Scientific Advisory Board
  • Steve Egge, MBA, Chief Commercial Officer
  • Rob Crotty, J.D., General Counsel and Chief Compliance Officer
  • EJ Brandreth, MBA, Senior Vice President, Quality Assurance
  • Shawn Bridy, MA, MBA, Senior Vice President, Business Development
  • Cheryl Elder, PharmD, Senior Vice President, Regulatory Affairs
  • Robert J. Juba Jr., Senior Vice President, Biological Manufacturing and Clinical Supply Management
  • Jeffrey Skolnik, M.D., Senior Vice President, Clinical Development
  • Dave Liebowitz, M.D. & Ph.D., Senior Vice President, Early-Stage Clinical Development
  • Simon X. Benito, Chairman of the Board, Inovio Pharmaceuticals
  • Roger D. Dansey, M.D., Chief Medical Officer at Seagen
  • Ann C. Miller, M.D., Former Head of Sanofi Oncology Global Marketing
  • Jay Shepard, Former President & CEO of Aravive
  • David B. Weiner, Ph.D., Executive Vice President, Director, Vaccine Center, The Wistar Institute
  • Wendy L. Yarno, MBA, Former Executive Vice President and Chief Marketing Officer at Merck & Co., Inc.
  • Lota S. Zoth, CPA, Former Chief Financial Officer, MedImmune
  • Rafi Ahmed, Ph.D., Director, Emory Vaccine Center, Emory University School of Medicine
  • Stanley A. Plotkin, M.D., Emeritus Professor, Wistar Institute and University of Pennsylvania; Principal, Vaxconsult

Last updated: 2024-12-31

Inozyme Pharma, Inc.

Inozyme Pharma, Inc. logo
Market Cap: Medium
Employees: Lowest

INZ-701

Inozyme Pharma, Inc. is a biopharmaceutical company focused on the development of therapeutics for rare disease conditions involving abnormal mineralization, particularly targeting ENPP1 and ABCC6 deficiencies.

Tags: ABCC6, ENPP1, INZ-701, biopharmaceutical, calciphylaxis, genetic diseases, mineralization, rare diseases, therapeutics

Symbol: INZY

Recent Price: $2.82

Industry: Biotechnology

CEO: Dr. Douglas A. Treco Ph.D.

Sector: Healthcare

Employees: 59

Address: 321 Summer Street, Boston, MA 02210

Phone: 857 330 4340

Leadership

  • Doug Treco, Ph.D., CEO, Chairman of Board of Directors
  • Gayle Gironda, Senior Vice President and Chief People Officer
  • Kurt Gunter, M.D., Senior Vice President and Chief Medical Officer
  • Soojin Kim, Ph.D., Senior Vice President and Chief Technical Operations Officer
  • Yves Sabbagh, Ph.D., Senior Vice President and Chief Scientific Officer, Chair of the Scientific Advisory Board
  • Sanjay S. Subramanian, M.S., MBA, Senior Vice President and Chief Financial Officer
  • Matt Winton, Ph.D., Senior Vice President and Chief Operating Officer
  • Axel Bolte, MBA, Co-founder, Senior Advisor and Member of Board of Directors
  • David Thompson, M.A., M.S., Ph.D., Senior Advisor, Member of Scientific Advisory Board
  • Sarah Bhagat, Ph.D., Director
  • Reinaldo M. Diaz, MBA, Director
  • Martin Edwards M.D., MBA, Director
  • Erik Harris, MBA, Director
  • Rob Hopfner, Rph, Ph.D., MBA, Director
  • Edward Mathers, Director
  • Lynne Sullivan, MST, Director

Last updated: 2024-12-31

Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. logo
Market Cap: High
Employees: Low

Re Sure Sealant; DEXTENZA; OTX-TKI; OTX-TIC; OTX-CSI

Ocular Therapeutix is a biopharmaceutical company that develops and commercializes therapies for eye diseases using bioresorbable hydrogel-based technology, offering products like Re Sure Sealant and DEXTENZA.

Tags: biopharmaceutical, eye care, hydrogel, ophthalmic devices, ophthalmology, therapy

Symbol: OCUL

Recent Price: $8.35

Industry: Biotechnology

CEO: Dr. Pravin U. Dugel M.D.

Sector: Healthcare

Employees: 267

Address: 24 Crosby Drive, Bedford, MA 01730

Phone: 781 357 4000

Leadership

  • Pravin U. Dugel, MD, Executive Chairman, President and CEO
  • Karen-Leigh Edwards, PhD, MBA, Chief Operations Officer
  • Peter Jarrett, PhD, Chief Technical Officer
  • Donald Notman, Chief Financial Officer and Chief Operating Officer
  • Nadia K. Waheed, MD, MPH, Chief Medical Officer
  • Jeffrey S. Heier, MD, Chief Scientific Officer
  • Steve Meyers, Chief Commercial Officer
  • Tracy Smith, Vice President, Human Resources
  • Sanjay Nayak, MBBS, PhD, Chief Strategy Officer
  • Peter K. Kaiser, MD, Chief Development Officer
  • Todd Anderman, JD, Chief Legal Officer and Corporate Secretary
  • Charles Warden, Lead Independent Director
  • Adrienne Graves, PhD, Director
  • Leslie Williams, Director
  • Richard Lindstrom, MD, Director
  • Seung Suh Hong, PhD, Director
  • Merilee Raines, Director

Last updated: 2024-12-31

Onconetix, Inc.

Onconetix, Inc. logo
Market Cap: Lowest
Employees: Lowest

Entadfi

Onconetix, Inc. is a biotechnology and pharmaceutical company focused on developing and commercializing transformative therapies to address global health challenges. The company’s products include Entadfi for benign prostatic hyperplasia and various innovative vaccine candidates.

Tags: Entadfi, biotechnology, healthcare, pharmaceutical, therapies, vaccines

Symbol: ONCO

Recent Price: $0.44

Industry: Biotechnology

CEO: Dr. Ralph Schiess Ph.D.

Sector: Healthcare

Employees: 12

Address: 201 East Fifth Street, Cincinnati, OH 45202

Phone: 513 620 4101

Last updated: 2024-12-31

Ovid Therapeutics Inc.

Ovid Therapeutics Inc. logo
Market Cap: Low
Employees: Lowest

OV101, OV329, OV350, OV882, OV815

Ovid Therapeutics Inc., a biopharmaceutical company based in New York, is dedicated to developing impactful medicines for neurological disorders. They have a range of drug candidates like OV101 and are involved in various clinical trials.

Tags: biopharmaceutical, clinical trials, medicine development, neurological disorders

Symbol: OVID

Recent Price: $0.96

Industry: Biotechnology

CEO: Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D.

Sector: Healthcare

Employees: 40

Address: 1460 Broadway, New York, NY 10036

Phone: 646 661 7661

Leadership

  • Jeremy M. Levin, D.Phil, MB BChir, Chief Executive Officer and Chairman
  • Meg Alexander, President and Chief Operating Officer
  • Zhong Zhong, Ph.D., Chief Scientific Officer
  • Jeffrey Rona, Chief Business and Financial Officer
  • Amanda Banks, M.D., Chief Development Officer
  • Julia Tsai, Ph.D., Senior Vice President of Clinical Development
  • Karen Bernstein, Ph.D., Director, Chair of the Compensation Committee, Member of the Audit and Nominating and Corporate Governance Committees
  • Barbara G. Duncan, MBA, Director, Chair of the Audit Committee, Member of the Nominating and Corporate Governance Committee
  • Bart Friedman, J.D., Lead Independent Director, Chair of the Nominating and Corporate Governance Committee, Member of the Audit and Compensation Committees
  • Michael Poole, M.D., FACP, Director, Member of the Audit and Compensation Committees
  • Kevin Fitzgerald, Ph.D., Director, Member of the Nominating and Corporate Governance Committee

Last updated: 2024-12-31

Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. logo
Market Cap: Lowest
Employees: Lowest

INTASYL therapeutic platform

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics using its INTASYL therapeutic platform to target tumor and immune cells by regulating genes of the immune system, focusing on products like PH-762, PH-894, and PH-804 for enhancing cancer immunotherapies in adoptive cell transfer.

Tags: ACT, BRD4, Biotechnology, Cancer, Immuno-Oncology, PD-1, TIGIT, Therapeutics

Symbol: PHIO

Recent Price: $1.90

Industry: Biotechnology

CEO: Mr. Robert J. Bitterman

Sector: Healthcare

Employees: 8

Address: 257 Simarano Drive, Marlborough, MA 01752

Phone: 508 767 3861

Last updated: 2024-12-31

Quoin Pharmaceuticals, Ltd.

Quoin Pharmaceuticals, Ltd. logo
Market Cap: Lowest
Employees: Lowest

QRX003

Quoin Pharmaceuticals, Ltd. is a specialty pharmaceutical company focused on developing therapeutic products for rare and orphan diseases, including QRX003 for Netherton Syndrome.

Tags: Netherton Syndrome, QRX003, QRX004, QRX006, orphan diseases, pharmaceuticals, rare diseases, therapeutics

Symbol: QNRX

Recent Price: $0.70

Industry: Biotechnology

CEO: Dr. Michael Myers Ph.D.

Sector: Healthcare

Employees: 4

Address: 42127 Pleasant Forest Court, Ashburn, VA 20148-7349

Phone: 703 980 4182

Last updated: 2024-12-31

Scilex Holding Company

Scilex Holding Company logo
Market Cap: Low
Employees: Low

ZTlido 1.8%

Scilex Holding Company is a biopharmaceutical company focused on developing and commercializing non-opioid management products for the treatment of acute and chronic pain, including its commercial product ZTlido 1.8% and several products in clinical trial stages.

Tags: biopharmaceutical, clinical trials, neuropathic pain, non-opioid pain management

Symbol: SCLX

Recent Price: $0.42

Industry: Drug Manufacturers - General

CEO: Mr. Jaisim Shah

Sector: Healthcare

Employees: 113

Address: 960 San Antonio Road, Palo Alto, CA 94303

Phone: 650-516-4310

Last updated: 2024-12-31

Scopus BioPharma Inc.

Scopus BioPharma Inc. logo
Market Cap: Lowest
Employees: Lowest

Duet Platform

Scopus Bio Pharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics for serious diseases with lead programs in immuno-oncology gene therapy.

Tags: biopharmaceutical, cancer treatment, gene therapy, immuno-oncology, therapeutics

Symbol: SCPS

Recent Price: $0.00

Industry: Biotechnology

CEO: Dr. Alan D. Horsager Ph.D.

Sector: Healthcare

Employees: 13

Address: 420 Lexington Avenue, New York, NY 10170

Phone: 212 479 2513

Last updated: 2024-12-31

Synlogic, Inc.

Synlogic, Inc. logo
Market Cap: Lowest
Employees: Lowest

Synthetic Biotic Medicines

Synlogic, Inc. is a clinical-stage biopharmaceutical company focused on the development of synthetic biotic medicines to treat metabolic and immunological diseases. The company's pipeline includes drug candidates for conditions such as phenylketonuria, homocystinuria, enteric hyperoxaluria, and solid tumors and lymphoma.

Tags: biopharmaceutical, drug development, immunological diseases, metabolic diseases, synthetic biotic

Symbol: SYBX

Recent Price: $1.40

Industry: Biotechnology

CEO: Mr. Antoine Awad

Sector: Healthcare

Employees: 6

Address: 301 Binney Street, Cambridge, MA 02142

Phone: 617 401 9975

Last updated: 2024-12-31